Nuheart was established in March 2014 and is dedicated to developing a novel concept for a heart pump treatment, from idea to clinical use. The Nuheart device represents the first percutaneous ventricular assist device (VAD) able to provide complete, long-term circulatory support for patients with severe heart failure. The Nuheart VAD will have the key advantage of low invasiveness (non-surgical) due to its delivery through a trans-catheter system, with markedly reduced resource demand and allowing for rapid mobilization of patients following the procedure. The “all-new” concept is based on an insertion of the pump through the venous system by customized delivery catheters. The pump docks to a connector between the atrial wall and the aorta and creates a channel through the two tissues, through which the VAD will directly pump blood from the left atrium into the aorta. Nuheart believes that its ventricular assist device (VAD) concept has the potential to be a global game changer, not only providing a better solution for current VAD-treated heart failure patients, but also offering a new treatment option to patients that currently are not eligible for VAD, therefore saving lives, extending lives, improving quality of life, and reducing the cost burden of health care on society.
- Home
- About
- VISIT ISRAEL
- Faculty
- PROGRAM
- Scientific Program
- GUIDELINES FOR ORAL PRESENTATION
- Satellite Symposia Sessions
- Abstract Submission
- Get Published in JACC: CV Interventions
- Complex coronary and Valve cases
- The israeli medtech workshop
- Academy of Innovation
- Meet the VC’s – Funding the future of health
- MedTech CEO-Only Forum
- Digital health day
- Supporting Partners
- Sponsorship
- Podcasts
- Startup compettion
- REGISTER NOW
- INVITATION LETTER
